Total Payments
$42,589
2024 Payments
$755.02
Companies
15
Transactions
123
Medicare Patients
390
Medicare Billing
$63,918
Payment Breakdown by Category
Consulting$36,160 (84.9%)
Research$3,512 (8.2%)
Food & Beverage$2,085 (4.9%)
Travel$814.67 (1.9%)
Education$17.66 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $36,160 | 29 | 84.9% |
| Unspecified | $3,512 | 13 | 8.2% |
| Food and Beverage | $2,085 | 76 | 4.9% |
| Travel and Lodging | $814.67 | 3 | 1.9% |
| Education | $17.66 | 2 | 0.0% |
Payments by Type
General
$39,078
110 transactions
Research
$3,512
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Foundation Medicine, Inc. | $31,720 | 26 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $3,567 | 14 | $0 (2024) |
| Clovis Oncology, Inc. | $3,299 | 15 | $0 (2019) |
| GlaxoSmithKline, LLC. | $1,975 | 2 | $0 (2024) |
| TESARO, Inc. | $1,185 | 28 | $0 (2019) |
| Genentech USA, Inc. | $129.66 | 6 | $0 (2019) |
| Amgen Inc. | $124.75 | 5 | $0 (2018) |
| Kyowa Kirin, Inc. | $117.25 | 5 | $0 (2019) |
| Covidien LP | $114.60 | 2 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $109.04 | 6 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $755.02 | 4 | Regeneron Pharmaceuticals, Inc. ($704.15) |
| 2023 | $657.76 | 2 | Regeneron Pharmaceuticals, Inc. ($657.76) |
| 2022 | $3,080 | 4 | Foundation Medicine, Inc. ($2,925) |
| 2021 | $5,209 | 8 | Foundation Medicine, Inc. ($2,540) |
| 2020 | $11,243 | 8 | Foundation Medicine, Inc. ($10,375) |
| 2019 | $4,975 | 20 | Foundation Medicine, Inc. ($4,600) |
| 2018 | $16,064 | 54 | Foundation Medicine, Inc. ($11,280) |
| 2017 | $604.47 | 23 | TESARO, Inc. ($262.75) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/18/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $24.51 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $168.23 | Research |
| Study: A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER • Category: ONCOLOGY | ||||||
| 03/18/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $535.92 | Research |
| Study: A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER • Category: ONCOLOGY | ||||||
| 12/19/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $325.56 | Research |
| Study: A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER • Category: ONCOLOGY | ||||||
| 02/15/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $332.20 | Research |
| Study: A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER • Category: ONCOLOGY | ||||||
| 12/13/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $28.47 | Research |
| Study: A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER • Category: ONCOLOGY | ||||||
| 07/14/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $116.17 | Research |
| Study: A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER • Category: ONCOLOGY | ||||||
| 06/07/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $2,925.00 | General |
| Category: ONCOLOGY | ||||||
| 04/12/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $10.85 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2021 | Myriad Genetic Laboratories, Inc. | myChoice CDx (Device) | Food and Beverage | Cash or cash equivalent | $23.05 | General |
| Category: Tumor DNA Genetic Oncology Analysis | ||||||
| 07/29/2021 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: ONCOLOGY | ||||||
| 07/20/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2021 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: ONCOLOGY | ||||||
| 03/19/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $390.58 | Research |
| Study: A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | ||||||
| 02/23/2021 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $415.00 | General |
| Category: ONCOLOGY | ||||||
| 01/27/2021 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 01/07/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $305.11 | Research |
| Study: A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | ||||||
| 11/25/2020 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $3,625.00 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2020 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $868.37 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 07/24/2020 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: ONCOLOGY | ||||||
| 05/22/2020 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID (Device), FOUNDATIONFOCUS, FOUNDATIONONE CDX | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: ONCOLOGY | ||||||
| 02/24/2020 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID (Device), FOUNDATIONFOCUS, FOUNDATIONONE CDX | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: ONCOLOGY | ||||||
| 01/24/2020 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID (Device), FOUNDATIONFOCUS, FOUNDATIONONE CDX | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | Regeneron Pharmaceuticals, Inc. | $2,202 | 8 |
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $868.37 | 1 |
| Libtayo Clinical Publication Program | Regeneron Pharmaceuticals, Inc. | $441.23 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 88 | 158 | $86,320 | $14,322 |
| 2022 | 4 | 113 | 175 | $98,126 | $16,780 |
| 2021 | 3 | 103 | 185 | $105,630 | $19,801 |
| 2020 | 2 | 86 | 149 | $86,310 | $13,015 |
Total Patients
390
Total Services
667
Medicare Billing
$63,918
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 76 | $49,400 | $8,180 | 16.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 48 | $24,000 | $3,464 | 14.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 34 | $12,920 | $2,679 | 20.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 85 | $54,726 | $9,206 | 16.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 37 | 40 | $15,200 | $2,897 | 19.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $11,200 | $2,500 | 22.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 34 | $17,000 | $2,177 | 12.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 50 | 126 | $80,700 | $14,453 | 17.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 41 | 47 | $16,530 | $3,566 | 21.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $8,400 | $1,782 | 21.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 61 | 118 | $76,700 | $11,143 | 14.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 25 | 31 | $9,610 | $1,872 | 19.5% |
About Dr. June Hou, M.D
Dr. June Hou, M.D is a Gynecology healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2007. The National Provider Identifier (NPI) number assigned to this provider is 1619192911.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. June Hou, M.D has received a total of $42,589 in payments from pharmaceutical and medical device companies, with $755.02 received in 2024. These payments were reported across 123 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($36,160).
As a Medicare-enrolled provider, Hou has provided services to 390 Medicare beneficiaries, totaling 667 services with total Medicare billing of $63,918. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecology
- Other Specialties Gynecologic Oncology
- Location Bronx, NY
- Active Since 04/13/2007
- Last Updated 03/30/2023
- Taxonomy Code 207VG0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1619192911
Products in Payments
- FOUNDATIONONE LIQUID (Device) $19,505
- FOUNDATIONONE CDX (Device) $12,215
- Rubraca (Drug) $3,299
- ZEJULA (Drug) $2,863
- LIBTAYO (Biological) $2,430
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $441.23
- Avastin (Biological) $129.66
- SANCUSO (Drug) $117.25
- TruClear (Device) $114.60
- Neulasta (Biological) $111.00
- Orilissa (Drug) $78.50
- FASLODEX (Drug) $51.40
- VARUBI (Drug) $46.72
- LYNPARZA (Biological) $44.54
- KEYTRUDA (Biological) $39.67
- LYNPARZA (Drug) $35.79
- ELAHERE (Drug) $26.36
- myChoice CDx (Device) $23.05
- BRILINTA (Drug) $21.85
- Ultra 2.0 (Device) $21.52
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecology Doctors in Bronx
Donna Henry, M.d, M.D
Gynecology — Payments: $16,667
Gynecology $16,667
Mrs. Aruna Mishra, M.d, M.D
Gynecology — Payments: $9,369
Gynecology $9,369
Dr. Carol Livoti, M.d.,F.a.c.o.g, M.D.,F.A.C.O.G
Gynecology — Payments: $2,922
Gynecology $2,922
Andrew Silverman, Md, MD
Gynecology — Payments: $365.69
Gynecology $365.69
Dr. Daryl Wieland, Md, MD
Gynecology — Payments: $339.51
Gynecology $339.51
Dr. Patrina Phillip, M.d, M.D
Gynecology — Payments: $317.73
Gynecology $317.73